Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Green, a former pharmacist and pharma ad copywriter whose resume includes such agencies as Grey Healthcare and KPR (since ...

Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

Pharmaceutical companies raise drug prices in U.S.; Korea faces minimal impact Global drug price hikes by major firms ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...